← Back to Analyst Consensus 
PHAR Buy
Pharming Group N.V.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 3, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 10, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| Mar 24, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 13, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Mar 21, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Mar 20, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Mar 14, 2025 | Oppenheimer | maintain | Outperform → Outperform | $39 | 52% |
| Mar 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Dec 17, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Dec 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Dec 11, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Dec 9, 2024 | Jefferies | initiate | — → Buy | $14 | 51% |
| Oct 28, 2024 | Oppenheimer | maintain | Outperform → Outperform | $30 | 52% |
| Oct 24, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Oct 15, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Oct 10, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Sep 26, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Aug 1, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| May 31, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Mar 14, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $37 | 44% |
| Aug 3, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $37 | 44% |
| Mar 28, 2023 | Oppenheimer | maintain | — → Outperform | $40 | 52% |
| Mar 27, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $37 | 44% |
| Feb 22, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $37 | 44% |
| Feb 16, 2023 | HC Wainwright & Co. | reiterate | — → Buy | $37 | 44% |
Price Target Trend
Apr 23, 2026 Oct 27, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days